On May 4, 2026, Scilex Holding Co's subsidiary ACEA Therapeutics signed a $1 billion Stock Acquisition Agreement to buy ACEA Pharma from Phoenix Asia, expected to close in Q2 2026. The deal will make ACEA Therapeutics an 82% owner of Phoenix Asia, contingent on certain regulatory approvals.